Cartesian Therapeutics (RNAC) Short term Debt (2016 - 2023)
Cartesian Therapeutics (RNAC) posted quarterly Short term Debt of $10.2 million for Q2 2023, up 211.57% year-over-year from $3.3 million in Q2 2022, and little changed quarter-over-quarter from $10.2 million in Q1 2023.
Cartesian Therapeutics (RNAC) Short term Debt (2016 - 2023) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Short term Debt for 8 consecutive years, with $10.2 million the latest figure, recorded in Q2 2023.
- In Q2 2023, Short term Debt rose 211.57% year-over-year to $10.2 million; the TTM figure through Jun 2023 stood at $10.2 million (up 211.57% YoY), while the FY2022 annual figure was $8.5 million, up 42.19% from the prior year.
- Short term Debt held at $10.2 million in Q2 2023 per RNAC's latest filing, from $10.2 million in the prior quarter.
- Across five years, Short term Debt topped out at $21.5 million in Q2 2019 and bottomed at $460000.0 in Q1 2021.
- Historically, Short term Debt has averaged $10.0 million across 5 years, with a median of $8.4 million in 2020.
- Annual changes were most pronounced in 2021 — Short term Debt plunged 97.27% — and 2023, when it soared 1368.1%.
- Cartesian Therapeutics' Short term Debt stood at $18.9 million in 2019, then slumped by 55.65% to $8.4 million in 2020, then decreased by 28.9% to $6.0 million in 2021, then jumped by 42.19% to $8.5 million in 2022, then gained by 20.75% to $10.2 million in 2023.
- Business Quant data shows RNAC's Short term Debt at $10.2 million in Q2 2023, $10.2 million in Q1 2023, and $8.5 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Cartesian Therapeutics | 265.54 Mn | 265.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 10.24 Mn |
| Mar 31, 2023 | 10.22 Mn |
| Dec 31, 2022 | 8.48 Mn |
| Sep 30, 2022 | 5.88 Mn |
| Jun 30, 2022 | 3.29 Mn |
| Mar 31, 2022 | 696,000.00 |
| Dec 31, 2021 | 5.96 Mn |
| Sep 30, 2021 | 4.13 Mn |
| Jun 30, 2021 | 2.29 Mn |
| Mar 31, 2021 | 460,000.00 |
| Jun 30, 2020 | 8.38 Mn |
| Mar 31, 2020 | 16.87 Mn |
| Dec 31, 2019 | 18.91 Mn |
| Sep 30, 2019 | 20.93 Mn |
| Jun 30, 2019 | 21.55 Mn |
| Mar 31, 2019 | 21.47 Mn |
| Dec 31, 2018 | 21.39 Mn |
| Sep 30, 2018 | 21.30 Mn |
| Jun 30, 2017 | 4.61 Mn |
| Mar 31, 2017 | 4.52 Mn |